-
2025-521322-14-00
4
Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation,
-
2025-521331-36-00
10
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%)
-
2025-521437-88-00
4
head and neck squamous cell carcinoma
-
2025-521632-12-00
5
Patients on Factor Xa inhibitor treatment needing an urgent interventi
-
2025-522872-10-00
5
Depressive episodes associated with Bipolar disorder I or II (Bipolar
-
2025-523555-66-00
5
Myelofibrosis
-
2025-524213-84-00
5
Patients with advanced or metastatic ER+ HER2- breast cancer
-
2025-524322-18-00
5
Non-active Secondary Progressive Multiple Sclerosis (SPMS)
-
2025-524344-35-00
5
Heart failure
-
2025-524697-42-00
5
Pleural infections
-
2025-524976-40-00
5
patients with influenza-induced acute hypoxemic respiratory failure
-
2026-525643-32-00
6
ulcerative colitis
-
2025-524408-30-01
5
2026-06-05
Metastatic hormone-sensitive prostate cancer
-
2025-521590-13-00
5
2026-05-28
Moderately to Severely Active Crohn’s Disease
-
2025-522996-27-00
5
2026-05-05
recurrent and/or metastatic squamous cell carcinoma of the head and ne
-
2025-522191-86-00
5
2026-04-02
Focal segmental glomerulosclerosis
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2024-512029-10-00
5
2025-12-05
Intermediate risk, non-muscle invasive bladder cancer
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2024-517102-29-00
5
2025-11-19
Intestinal Malabsorption
-
2025-521775-31-00
5
2025-11-12
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
-
2023-507658-34-00
10
2025-09-19
Membranous Nephropathy
-
2024-516646-19-00
5
2025-08-15
Type 2 diabetic patients with no prior cardiovascular (CV) events
-
2024-519113-59-00
4
2024-11-20
Hepatocellular carcinoma